.Pharmacolibrary.Drugs.ATC.P.P01BA02

Information

Hydroxychloroquine is an antimalarial and immunomodulatory drug that is approved for treatment of malaria, rheumatoid arthritis, and systemic lupus erythematosus. It has also been investigated for off-label uses including COVID-19, though it is not approved for this indication.

Pharmacokinetics

Population pharmacokinetics in healthy adults following oral administration.

References

1. Morita, S, et al., & Yokota, N (2016). Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. Therapeutic drug monitoring 38(2) 259–267. DOI:10.1097/FTD.0000000000000261 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26587870

2. Balevic, SJ, et al., & Cohen-Wolkowiez, M (2019). Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. Clinical pharmacokinetics 58(4) 525–533. DOI:10.1007/s40262-018-0712-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/30255310

3. Shimizu, M, et al., & Yokogawa, N (2023). Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment. Modern rheumatology 33(5) 953–960. DOI:10.1093/mr/roac113 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36112484

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)